Utama › Kanser Esofagus › Pennsylvania
Kajian klinikal Kanser Esofagus di Pennsylvania
29 kajian untuk Kanser Esofagus sedang mencari peserta di lokasi di Pennsylvania.
Bandar di Pennsylvania
Teks kajian rasmi (Bahasa Inggeris)
Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- IRMC Cancer Center, Indiana
- UPMC Hillman Cancer Center - New Castle, New Castle
- dan 2 lagi
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07059884Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Christiana Care Health System-Concord Health Center, Chadds Ford
- dan 8 lagi
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07283939A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05319730Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- dan 7 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069DESTINY-PANTUMOUR04
- Research Site, Philadelphia
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 130 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07124000A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
- University of Pennsylvania (Data Collection Only), Philadelphia
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06123338Pan-tumor MRD Study
- Lancaster General Hospital (UPenn), Lancaster
- Guthrie Foundation, Sayre
- Cancer Care Associates of York (CCAY), York
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06605404Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- University of Pittsburgh Medical Center, Pittsburgh
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07213791Prehabilitation in High-risk Oncologic Surgery
- Fox Chase Cancer Center - Philadelphia, Philadelphia
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07638410Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07217704ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT07812805Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Hershey
- Research Site, Philadelphia
- Research Site, Pittsburgh
- dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07431281Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06445972Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06469944Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
- University of Pennsylvania, Philadelphia
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT00288119A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- University of Pennsylvania, Philadelphia
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT03526835Lead-212 PSV359 Therapy for Patients With Solid Tumors
- University of Pittsburgh Medical Center, Pittsburgh
Mengambil pesertaFasa 1/2
Umur 18 hingga 90 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06710756Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
- UPMC Hillman Cancer Center, Pittsburgh
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Mei 2026 · NCT06872515Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- UPMC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT07223424Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Apr 2026 · NCT00260559Esophageal Cancer Risk Registry
- Department of Cardiothoracic Surgery, Pittsburgh
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Apr 2026 · NCT00260585The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Allegheny Health Network, Pittsburgh
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mac 2026 · NCT04075305PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
- Thomas Jefferson University Hospital, Philadelphia
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Feb 2026 · NCT05775939VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Cancer Care Associates of York (site 206), York
Mengambil pesertaFasa 1/2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 11 Dis 2025 · NCT03556228SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
- AHN West Penn Hospital, Pittsburgh
Mengambil pesertaFasa 1
Umur 18 hingga 69 · Semua jantina · Dikemas kini 3 Jun 2025 · NCT07001592Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.